LRRK2 and Parkinson disease: Centrosomal cohesion deficits were further observed in immortalized lymphocytes (LCLs) from a cohort of G2019S-LRRK2 PD patients as compared to healthy controls, and were reverted by the LRRK2 kinase inhibitor MLi2 in all cases52.